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Extensive β-amyloid (Aβ) deposits in brain parenchyma in the form of senile plaques and in blood vessels in the form of amyloid
angiopathy are pathological hallmarks of Alzheimer’s disease (AD). The mechanisms underlying Aβ deposition remain unclear.
Major eﬀorts have focused on Aβ production, but there is little to suggest that increased production of Aβ plays a role in Aβ
deposition, except for rare familial forms of AD. Thus, other mechanisms must be involved in the accumulation of Aβ in AD.
Recent data shows that impaired clearance may play an important role in Aβ accumulation in the pathogenesis of AD. This review
focuses on our current knowledge of Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE),
insulin-degrading enzyme (IDE), angiotensin-converting enzyme (ACE), and the plasmin/uPA/tPA system as they relate to amy-
loid deposition in AD.
Copyright © 2006 Deng-Shun Wang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Alzheimer’s disease (AD) is the commonest cause of senile
dementia and increases in frequency with age. Clinically, AD
is characterized by early and progressive memory loss due to
neuronal and synaptic loss in the cortex and limbic struc-
tures, including the hippocampus and amygdala. In later
stages of the disease process, the extensive involvement of
cortical and subcortical regions results in loss of higher cog-
nitive abilities, including speech and praxis, and in impaired
motor abilities. Grossly, AD brains show global atrophy and
reduced weight and volume. Histologically, AD is character-
ized by amyloid plaques, neuroﬁbrillary tangles, dystrophic
neurites, extensive neuronal loss, and gliosis.
Although beta-amyloid (Aβ) accumulation and senile/
neuritic plaque formation are striking morphological hall-
marksofADandwidelyusedintheneuropathologicdiagno-
sis of AD, it is clearly recognized that amyloid deposition in
thebrainparenchymaandinvesselsalsoiscommonfornon-
demented individuals in advanced age. Many possible expla-
nations for excessive Aβ deposition have been put forward,
including increased production, decreased degradation, and
abnormal transport between brain parenchyma and plasma
or CSF [1–3]. Although overproduction of Aβ is critical to
the pathogenesis of some forms of familial AD, there is still
little evidence to suggest that increased Aβ production is
important in amyloid deposition in aging and sporadic AD.
Recently, the role of degradation has been increasingly rec-
ognized in Aβ homeostasis. Several enzymes have been de-
scribed with a range of abilities to degrade Aβ. This review
will focus on enzymes capable of degrading Aβ and their po-
tential signiﬁcance to the pathogenesis of AD.
THE AMYLOID CASCADE HYPOTHESIS
The mechanisms underlying the pathogenesis of AD remain
unclear and are hotly debated. One proposal focuses on Aβ
production and deposition, the so-called amyloid cascade
hypothesis (Figure 1)[ 4–6]. This hypothesis posits that in-
creased Aβ production and deposition plays the key role in
triggering neuronal dysfunction and death in AD. Evidence,
including Aβ deposition in AD brain, the toxic properties of
Aβ to neurons in vitro, and the identiﬁcation of mutations
in amyloid precursor protein (APP) in familial early onset
AD have supported the amyloid cascade hypothesis. Based
on this theory, tremendous eﬀorts had been made during the
last decade to uncover the mechanisms underlying the pro-
duction of Aβ. From these studies it has been shown that se-
quential cleavage of APP by β-secretase and γ-secretase gen-
erates Aβ peptides (Figure 2)[ 7, 8]. Indeed, pharmacologic
intervention targeted at Aβ generation through inhibitors
of β-site cleaving enzyme (BACE) and γ-secretase is being2 Journal of Biomedicine and Biotechnology
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Figure 1: Amyloid cascade hypothesis. Aβ is a normal metabo-
lite which, under physiological conditions, is constantly produced
and quickly degraded. Due to genetic defects such as mutations
in APP, PS1, or PS2, Aβ production is increased, resulting in fa-
milial AD. A similar phenotype can occur with reduction in the
Aβ catabolic pathways. Accumulating Aβ will initially oligomer-
ize, gradually form ﬁbrils, and culminate in microscopically visible
amyloidplaques.SolubleandﬁbrillarAβandassociatedplaquepro-
teins are toxic to neurons, resulting in synaptic loss, the formation
of neuroﬁbrillary tangles, and eventual neuronal death and AD [5].
widely pursued [9, 10]. Attempts to block or regulate those
two enzymes together with immunotherapy aimed at reduc-
ing brain Aβ have been or will soon be tried in AD patients
[9, 11–13].
CANDIDATE ENZYMES FOR Aβ DEGRADATION
Altering catabolism is another way to reduce Aβ levels
in the brains of AD. Many proteases or peptidases have
been reported with the capability of cleaving Aβ either
in vitro or in vivo. These include neprilysin (NEP) [14–
16], endothelin-converting enzyme (ECE)-1 [17], insulin-
degrading enzyme (IDE) [18–20], angiotensin-converting
enzyme (ACE) [21], uPA/tPA-plasmin system [22, 23],
cathepsin D [24, 25], gelatinase A [26], gelatinase B [27],
matrix metalloendopeptidase-9 [28], coagulation factor XIa
[29], antibody light chain c23.5 and hk14 [30], and α2-
macroglobulin complexes [31]. Many of them have more
than one cleavage site in the Aβ peptide (Figure 3). The ba-
sic biological features of these enzymes are summarized in
Table 1. There are probably other proteases with potential to
cleave Aβ if all peptide bonds are taken into consideration,
but only those physiologically or pathologically relevant are
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Figure 2: Aβ biogenesis. Normally, Aβ is derived from the trans-
membrane region of amyloid precursor protein (APP) through the
sequential cleavage by BACE and γ-secretase. Under physiological
conditions, Aβ maintains a steady-state level and is necessary for
multiple physiological functions [168]. In AD, Aβ production is in-
creasedduetomutationsinAPPand/orinpresenilin(PS1andPS2)
genes.Thereisanα-secretasecleavagesitelocatedbetweenβ-andγ-
secretase cleavage sites that generates soluble, nonpathogenic pep-
tides [8].
discussed. Among them, NEP, IDE, ECE, ACE and plasmin,
tissue plasminogen activator (tPA), and urokinase-type plas-
minogen activator (uPA) system are the most promising Aβ-
degrading candidates.
NEPRILYSIN (NEP)
NEP is also known as neutral endopeptidase-24.11, EC
3.4.24.11, enkephalinase, neutrophil cluster-diﬀerentiation
antigen 10 (CD10), or common acute lymphoblastic leuke-
mia antigen (CALLA) [32–38]. In humans, the NEP gene
is located on chromosome 3q21–q27 and contains 24 exons
[39, 40]. NEP is composed of 750 amino acids with a cal-
culated molecular weight of approximately 86kDa [41]. Be-
causeofabundantposttranslationalmodiﬁcations,especially
glycosylation [42], NEP from human brain tissues migrates
between 97–110kDa on denaturing gel electrophoresis. As a
plasma membrane-bound glycoprotein, NEP is composed of
a short N-terminal cytoplasmic tail, a membrane-spanning
domain, and a large C-terminal extracellular catalytic do-
main. The latter contains a HExxH zinc-binding motif [43,
44], which facilitates the hydrolysis of extracellular oligopep-
tides (< 5kDa) on the amino side of hydrophobic residues,
such as the small, hydrophobic Aβ40 and Aβ42 peptides.
NEP is widely expressed in many normal tissues includ-
ing the brush-border of intestinal and kidney epithelial cells,
neutrophils, thymocytes, lung, prostate, testes, and brain
[45–49]. In the brain, it is expressed on neuronal plasma
membranes, both pre- and postsynaptically [50, 51], and is
most abundant in the nigrostriatal pathway, as well as in
brain areas vulnerable to amyloid plaque deposition, such as
the hippocampus [43, 52].Deng-Shun Wang et al 3
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Figure 3: Cleavage sites of Aβ by various enzymes including NEP (N) [14, 169, 170], ECE (E) [17, 169], IDE (I) [170, 171], plasmin (P)
[172], and ACE (A) [21]. β: γ-secretase; γ: γ-secretase; 40: Aβ40; 42: Aβ42. Modiﬁed from [173].
Table 1: Features of selected Aβ-degrading enzymes.
Protease a.k.a. Class Subcellular location Substrates in addition to Aβ
Neprilysin
CD10, CALLA,
EC 3.4.24.15
M
Cellular & intracellular
membrane including
presynaptic membrane
Enkephalin, cholecystokinin, neuropeptide Y,
substance P, opiod peptides, atrial natriuretic
peptides, bombesin-like peptides, chemotatic
peptides, adrenocorticotropin homone (ACTH)
Insulin-degrading enzyme
EC 3.4.24.56
Insulysin, IDE
M
Cytosol, cellular, and Insulin, glucagon, atrial natriuretic factor,
intracellular membrane β-endophin amylin, APP intracellular domain
extracellular space TGFα
Endothelin-converting enzyme EC 3.4.24.71 M Trans-Golgi network Big endothelin, substance P, bradykinin,
ECE cell surface oxidized insulin B chain
Angiotensin-converting enzyme
EC 3.4.15.1;
M
plasma membranes
perinuclear region
Angitensin-I, enkaphalins, bradykinin ACE; dipeptidyl
carboxypeptidase
Plasmin/uPA/tPA
EC 3.4.21.31
S Extracellular space ﬁbrin, plasminogon, & other matrix proteins
tissue plasminogen
activator for tPA;
urokinase-type
plasminogen activator
for uPA
Note: a.k.a. is also known as M: metalloproteases and S: serine.
The ﬁrst clue that NEP was involved in Aβ degradation
w a sp r o v i d e db yH o w e l le ta l[ 14]. Using high-performance
liquid chromatography (HPLC) combined with mass spec-
troscopic analysis, they found that NEP cleaved Aβ between
residues Glu3-Phe4, Gly9-Trp10, Phe19-Phe20, Ala30-Ile31,
and Gly33-Leu34. The true breakthrough demonstrating the
importance of NEP was demonstration that NEP was the
rate-limiting enzyme for Aβ d e g r a d a t i o ni nv i v om a d eb y
Iwata et alin 2000 [15].Afterinjecting radio-labeled Aβ pep-
tides into rat hippocampus in the presence or absence of var-
ious protease inhibitors, the resultant Aβ fragments were an-
alyzed by HPLC equipped with ﬂow scintillation. Iwata and
coworkers found that Aβ42 was degraded in the hippocam-
pus, with a half-life of 17.5 minutes and with Aβ10–37 as
the major catabolic intermediate. Infusion of thiorphan, a
speciﬁc NEP inhibitor [53], directly into rat hippocampus
for 3 days elevated endogenous Aβ levels, and infusion for
30 days resulted in further endogenous Aβ accumulation
and accumulation of extracellular Aβ deposits resembling
amyloid plaques [15, 54]. They also found that almost all
radio-labeled Aβ42 could be recovered from the hippocam-
pus 1 hour after the injection, which suggested that Aβ clear-
ancedependspredominantlyonlocalproteolysis,ratherthan
transport across the blood brain barrier into the blood or
into the cerebrospinal ﬂuid [15]. Interestingly, in another
independent study, it was found that radio-labeled Aβ40
injected into mouse brain was more readily transferred to
blood, compared with Aβ42, suggesting that the relative con-
tributions of degradation and transport to brain Aβ clear-
ance might be diﬀerent for these two peptides [55]. Fur-
thermore, it had been found that NEP was able to degrade
not only monomeric, but also oligomeric forms of both4 Journal of Biomedicine and Biotechnology
Aβ40 and Aβ42 [56], both intracellularly and extracellularly
[57].
T h er o l eo fN E Pi nA β degradation was solidiﬁed by
studies in transgenic mice. In partially NEP deﬁcient ani-
mals, the degradation of both endogenous and exogenous
Aβ peptides was tightly correlated with gene dose, suggesting
that even partial down-regulation of NEP activity could con-
tribute to Aβ accumulation. These studies also established
that NEP is a physiologically relevant Aβ degrading enzyme
[16]. On the other hand, overexpression of NEP by gene
transfer in amyloid-depositing transgenic mice slowed, and
in some cases reversed Aβ deposition [54, 58–60].
Studies in human subjects have also supported the no-
t i o nt h a tN E Pp l a y sak e yr o l ei nb r a i nA β metabolism and
AD pathogenesis. As mentioned above, aging is one of the
most important risk factors for AD [61] and is associated
with the accumulation of Aβ even in cognitively normal el-
derly [62, 63]. Although systematic study of the relation-
ship between NEP and aging in humans remains to be done,
aging mice show region selective decreases in NEP mRNA
expression [52, 64, 65]. These changes occurred despite
maintenance of synaptic and neuronal numbers suggesting
gene speciﬁcity. Immunohistochemical studies on AD brains
have revealed NEP immunoreactivity in senile plaques [49].
QuantitativeanalysisshowedthatbothNEPmRNAandpro-
tein were signiﬁcantly lower in AD than in age-matched nor-
mal control brains [65–68]. Reductions occurred selectively
in the regions most vulnerable to AD pathology, but not in
o t h e rb r a i na r e a ss u c ha sc e r e b e l l u mo ri np e r i p h e r a lo r g a n s
[65, 66]. NEP was also decreased in the cerebrospinal ﬂuid
(CSF) of prodromal Alzheimer’s disease patients [69], con-
sistent with cause and eﬀect. Interestingly, an inverse rela-
tionship between NEP and Aβ levels in AD brain vascula-
ture has been reported. These data suggested that NEP may
play a role in cerebral amyloid angiopathy (CAA), another
very common pathological change found in AD brains [70].
Consistentwiththeseﬁndings,Aβ mutationsidentiﬁedinfa-
milial AD found in Dutch, Flemish, Italian, and Arctic fami-
liesdonotincreaseAβ production,butrathercausepresenile
parenchymal amyloidosis and CAA [71].
Recent data from our study showed that NEP decreased
in AD brains, but not in pathological aging (PA), a term to
describe neurologically normal individuals with high brain
amyloid burden (suﬃcient to diagnose AD with the Khacha-
turian criteria), but minimal or no neuroﬁbrillary degener-
ation (Braak neuroﬁbrillary tangle stages of three or less)
[63, 72]. Interestingly, NEP levels were inversely correlated
with a range of amyloid measures including senile plaque
c o u n t sa n dl ev e l so fA β40 and Aβ42 in cortical homogenates.
The NEP levels were also correlated with clinical cognitive
scores, with highest levels of NEP in those with best per-
formance on clinical measures, regardless of whether or not
there were cortical amyloid deposits [72]. These results sug-
gest that the deposition of Aβ in AD and PA brains diﬀers in
some way, either quantitatively or qualitatively. The results
were not merely due to synaptic loss in AD, but also not in
PA as measured by synaptic markers since NEP was not de-
creased in frontal dementia with decreased synaptic markers.
These data support the hypothesis that decreased NEP con-
tributes to Aβ deposition in AD, but perhaps in means that
are not entirely linked to visible amyloid deposition [72],
perhaps implicating failed degradation of toxic soluble inter-
mediates in AD.
Taken together, these data indicate that NEP is an im-
portant enzyme that contributes to the normal metabolism,
accumulation, and perhaps toxicity Aβ in AD.
ENDOTHELIN-CONVERTING ENZYME (ECE)
Endothelin (ET) is a potent vasoconstrictive peptide pro-
duced in vascular endothelial cells [73]. In addition, ET also
plays an important role in early development of the neural
crest and, thus, organogenesis [74]. Endothelin-converting
enzyme (ECE) is a transmembrane metalloprotease that cat-
alyzes the conversion of pro-ET (also referred to big-ET)
into vasoactive endothelin. So far, two diﬀerent isoforms of
ECE—ECE-1andECE-2—havebeenclonedinhumans[75–
77]. It has been estimated that expression of ECE-2 is only 1–
2% as much as the more abundant ECE-1 based on compar-
ativemRNAtranscriptlevelsinendothelialcells[78].Studies
have suggested that ECE-1, but not ECE-2, is a possible brain
Aβ-degrading enzyme [17].
ECE-1 consists of 758 amino acids [79] and is the
major enzyme responsible for speciﬁc cleavage of biologi-
cally inactive pro-ET-1 to active ET-1 in vascular endothe-
lial cells. It is a membrane-bound type II metalloprotease
and shares signiﬁcant sequence identity (about 38% homo-
logue at the amino acid level) with NEP. ECE-1 is abun-
dantly expressed in the vascular endothelial cells of all or-
gans and is also widely expressed in nonvascular cells of
many tissues, including lung, pancreas, testis, ovary, adrenal
gland, and kidney [75, 80–83]. Recent systematic immuno-
histochemical analyses have shown ECE-1 widely expressed
in human brain, including neurons in the diencephalon,
brainstem, basal nuclei, cerebral cortex, cerebellar hemi-
sphere, amygdala, and hippocampus [84, 85]. Four isoforms
of ECE-1 have been identiﬁed to date [75, 86–90]. All of
them are encoded by a single gene located on chromosome
1 (1p36), and they diﬀer in their cytoplasmic tail domains
throughalternativepromoterusage.Thefourisoformscleave
pro-ET with similar eﬃciency, but they diﬀer in their tis-
sue distribution and subcellular localization [87, 90]. Hu-
man ECE-1a is localized predominantly in plasma mem-
brane. Human ECE-1c and ECE-1d have also been reported
to be localized in plasma membrane, but also in intracellu-
lar compartments. In contrast, human ECE-1b is expressed
exclusively intracellularly, particularly in Golgi-like struc-
tures and the cytoplasmic face of the plasma membrane [90–
92].
Although both ECE-1 and NEP are metalloendopepti-
dases and thus subject to competitive inhibition by the met-
alloprotease inhibitors nanomolar concentrations of thior-
phan and phosphoramidon can inhibit NEP, whereas ECE-
1 is inhibited only at micromolar concentrations of phos-
phoramidon, and it is insensitive to thiorphan [53]. Another
diﬀerence is that ECE-1 is active only at neutral pH, whileDeng-Shun Wang et al 5
NEP is active over a slightly wider pH range (pH 6.5–7.5)
[72, 93].
By using HPLC, mass spectrometry, and N-terminal se-
quence analysis, Eckman and her colleagues provided the
ﬁrst evidence that ECE-1 may be involved in the metabolism
of Aβ. They found that ECE-1 expressed in cultured Chinese
hamster ovary cells that lack endogenous ECE activity, re-
duced the concentration of extracellular Aβ by up to 90%. In
vitro, recombinant ECE-1 cleaves synthetic Aβ40 in at least
three sites, resulting in formation of Aβ fragments Aβ1–16,
Aβ1–17, Aβ1–19, and Aβ20–40 [17]. In mice deﬁcient for
ECE-1 and the closely related ECE-2, both Aβ40 and Aβ42
levels were signiﬁcantly higher when compared with age-
matched wild-type littermate controls. Taken together, the
results suggest that ECE activity might be an important fac-
tor involved in Aβ clearance in vivo [94]. How important is
ECE-2 in this process is yet to be determined, and direct ev-
idence that ECE contributes to Aβ deposition in human AD
brains remains to be determined.
INSULIN-DEGRADING ENZYME (IDE)
IDE is also known as EC 3.4.24.56, insulin protease, in-
sulysin, or insulinase [95, 96]. Cloned human IDE consists
of 1019 amino acids [97]. The IDE gene was mapped to
chromosome 10q23–q25, which made it a candidate gene
for the Alzheimer disease-6 locus (known as AD6) [98, 99].
It is a zinc metalloendopeptidase that hydrolyzes multiple
peptides, including insulin, glucagon, atrial natriuretic fac-
tor, transforming growth factor-α, β-endorphin, amylin, and
the APP intracellular domain (AICD) in addition to Aβ
[100, 101]. Puriﬁed IDE from several mammalian tissues,
including blood cells, skeletal muscle, liver, and brain, mi-
grates as a 110kDa band on denaturing gel electrophore-
sis, but it migrates as a 300kDa band under nondenatur-
ing conditions. These results suggest that native IDE exists
as a mixture of dimers and tetramers [100, 102]. IDE is
active at neutral pH and dimers have greater activity than
monomers [96, 103, 104]. Subcellularly, IDE is primarily lo-
cated in the cytosol, although it also had been found in per-
oxisomes [105], plasma membrane [106, 107], and in a se-
creted form [20].
Kurochkin and Goto reported the ﬁrst evidence that IDE
might involved in Aβ degradation [18]. They found that
125I-labeled synthetic Aβ speciﬁcally cross-linked to a single
110kDa protein, which was shown to be IDE, in cytosol frac-
tions from rat brain and liver. Puriﬁed rat IDE eﬀectively de-
graded synthetic Aβ in vitro. Subsequently, it was shown that
an IDE-like activity from soluble and synaptic membrane
fractions from postmortem human and fresh rat brain also
degraded Aβ peptides [19, 108]. Studies in the cultured cells
also proved that IDE could degrade both endogenous and
synthetic Aβ in vitro [20, 109]. The overexpression of IDE
in Chinese hamster ovary cells resulted in a marked reduc-
tion in levels of intracellular detergent-soluble Aβ,a sw e l la s
r e d u c e dl e v e l so fe x t r a c e l l u l a rA β40 and A42 [110].
Transgenic mice overexpressing IDE showed signiﬁcant
reductions of total amyloid burden and improved survival
rates[58], while IDE knockout mice demonstrated a clear el-
evation of brain Aβ and the APP intracellular domain. Addi-
tionally, heterozygous mice exhibited Aβ levels that were in-
termediate between wild-type controls and knock-out mice,
indicating that IDE aﬀected Aβ level in a gene-dose depen-
dent manner [111, 112].
Immunohistochemical studies showed that IDE was pri-
marily expressed in neurons, but was also located in senile
plaques, in AD brain [113]. The ﬁnding that IDE mRNA and
protein were reduced in the hippocampus of AD patients, es-
pecially in APOE e4 carriers, suggested that APOE e4 might
be sensitive to IDE expression levels with downstream ef-
fects on Aβ metabolism [114]. Like NEP, IDE also showed
progressively decreased expression that was age- and region-
dependent [65]. Thus, strong evidence exists that IDE is an-
other important Aβ-degrading enzyme that may play a role
in the amyloid pathology of AD.
ANGIOTENSIN-CONVERTING ENZYME (ACE)
Angiotensin-converting enzyme, also known as EC 3.4.15.1,
dipeptidyl carboxypeptidase, or ACE, is a membrane-bound
zinc metalloprotease. At least two ACE isotypes (ACE1 and
ACE2) had been cloned in humans, thus far [115]. ACE is
composed of 732 amino acids [116] and contains two pro-
teolytically active domains that are located at N- and C-
termini, respectively [117]. The major function of ACE is
to catalyze the conversion of angiotensin I (AngI) to an-
giotensin II (AngII), which plays an important role in main-
taining blood pressure, body ﬂuid, and sodium homeostasis
[118].
ACE is also widely expressed both outside and within the
CNS. In the brain, ACE was found at highest levels in cir-
cumventricular organs such as the subfornical organ, area
postrema, and themedian eminence[119].Itwasdetectedin
other areas as well, including the caudate nucleus, putamen,
substantia nigra pars reticularis, nucleus of the solitary tract
(NTS), dorsal motor nucleus, median preoptic nucleus, and
choroid plexus in rat, human, rabbit, sheep, monkey [120].
Most of the evidence for the potential relationship be-
tween ACE and AD has come from human genetic studies
[121–127]. Patients at higher AD risk had an insertion (I)
polymorphism within intron 16 of the ACE gene, which was
associated with AD [121]. Interestingly, patients with a dele-
tion polymorphism had a lower risk of AD [123, 124]. Ge-
neticanalysisofpostmortemADbrainsshowedhomozygous
I/I was associated with higher brain Aβ levels compared to
D/D allele carriers [128]. Results from earlier preclinical and
clinical studies suggested that ACE might have a role in the
modulation of cognitive memory processes in the rat and in
humans [129].
Hu and coworkers provided the ﬁrst evidence that ACE
could signiﬁcantly inhibit the aggregation, deposition, and
cytotoxicity of Aβ in vitro by cleavage of Aβ at Asp7-Ser8.
This was a surprising ﬁnding given the known speciﬁcity
of ACE [130] and the failure of ACE inhibitors to alter Aβ
degradation in vivo [15, 16]. Whether this discrepancy was
due to diﬀerent experimental systems (eg, in vitro versus in6 Journal of Biomedicine and Biotechnology
vivo) is not clear. Further work in other experimental sys-
tems such as ACE-deﬁcient or knockout animals is needed to
clarify the role ACE might have in amyloid pathology in AD.
A very recent report by Hemming and Selkoe, showed
that ACE expression promoted the degradation of endoge-
nous Aβ40 and Aβ42 [131]. Using site-directed mutagenesis,
theyalsoshowedthatbothN-andC-terminalproteolytically
active domains contributed to Aβ degradation. Captopril, a
widely prescribed ACE inhibitor blocked Aβ cleavage in cul-
t u r em e d i u m .T h i si sp o t e n t i a l l yv e r yi m p o r t a n to b s e r v a t i o n
becauseitsuggestswidelyusedACEinhibitorscouldincrease
cerebral Aβ levels in patients with hypertension.
Unlike other candidate Aβ-degrading enzymes discussed
above, the levels of both ACE protein and activity were ele-
v a t e di np o s t m o rt e mb r a i n s[ 132–134]. Given that other Aβ-
degrading enzymes such as NEP and IDE are decreased in
AD brains compared to age-matched healthy controls [65–
68, 72], ACE may show compensatory up-regulation in re-
sponse to accumulating Aβ. Along with concurrent evalua-
tion of NEP, ECE, IDE, ACE, and possibly others in the same
panel of postmortem human brains with the spectrum of
pathology from normal aging, early and advanced AD will
be helpful in clarifying respective functions of these pro-
teases.
PLASMIN, TISSUE PLASMINOGEN ACTIVATOR (tPA),
AND UROKINASE-TYPE PLASMINOGEN
ACTIVATOR (uPA)
Plasmin is a serine protease important in the degradation
of many extracellular matrix components [135]. The princi-
palcomponentsofthissystemincludeplasminogen/plasmin,
tissue plasminogen activator (tPA), urokinase-type plasmin-
ogen activator (uPA) [136]. tPA and uPA cleave plasmino-
gen to yield the active serine protease, plasmin. In the ner-
vous system, plasminogen and uPA are expressed in neu-
rons, while tPA is synthesized by neurons and microglial cells
[137]. The plasmin system is involved in many normal neu-
ral functions, such as neuronal plasticity [138], learning, and
memory [139].
Several studies showed that Aβ aggregates could substi-
tute for ﬁbrin aggregates in activating tPA, and suggested
that tPA may be activated by Aβ in AD [140, 141]. Later,
it was reported that brain plasmin enhanced Aβ degrada-
tion [142, 143], while plasmin and its activity were decreased
in AD brains [142, 144]. In cultured cells puriﬁed plasmin
signiﬁcantly decreased the level of neuronal injury induced
by aggregated Aβ, presumably by degrading Aβ [143, 145].
However, the in vivo eﬀect of plasmin could be very dif-
ferent given that serum amyloid P, that is associated with
amyloid pathology in AD brain, is able to prevent proteol-
ysis of puriﬁed cerebral Aβ [146]. Indeed, plasminogen deﬁ-
cient mice did not show increased Aβ in the brain or in the
plasma and suggested that plasmin does not regulate steady-
state Aβ levels in nonpathologic conditions [147], although
it might be involved in the degradation of pathological Aβ
aggregates.
OXIDATIVE DAMAGE TO Aβ-DEGRADING
ENZYMES
Some studies have indicated that genetic polymorphisms of
Aβ-degrading enzymes including NEP, IDE, ACE might be
associated with AD [122, 125, 127, 148–155], although these
results remain controversial [128, 156–161]. Further clinical
andpathologic studiesoflargenumbers ofindividuals carry-
ing various mutations in possible Aβ-degrading enzymes are
needed to clarify this issue.
In addition to genetics, many environmental factors such
as oxidative stress can potentially impair the activity of Aβ-
degrading enzymes [162–164]. Recent data showed that NEP
and IDE might be substrates for oxidative damage during ag-
ing and in AD [65, 68]. Both NEP and IDE from AD brain
tissues could be modiﬁed by 4-hydroxy-nonenal (HNE), a
by-product of lipid peroxidation [165]. The ratio of oxidized
NEP from frontal cortex [68] and IDE from hippocampus
[65] was greater in AD brains than in age-matched controls.
Studies reported by Russo et al failed to conﬁrm these ﬁnd-
ings [166]. In their study, they found that NEP mRNA from
AD brains was signiﬁcantly lower than in controls, but not
NEP protein [166], which was contradictory to several pre-
vious reports [65–68]. One possible reason for such a dis-
crepancy might be purely technical, reﬂecting diﬀerent im-
munoprecipitation protocols and incomplete antigenic re-
covery [166]. Although very recent data conﬁrmed that both
recombinant IDE and the extracellular domain of NEP were
modiﬁed by HNE in vitro [167], additional, in vivo studies
of neuronal proteases are needed to clarify this potentially
very important mechanism for Aβ deposition in AD devel-
opment.
SUMMARY
Since the majority of AD cases are sporadic without clear ge-
neticcauses,andthatevenalargepercentageoffamilialcases
cannot be explained by the overproduction of Aβ, multiple
factors are likely involved in the pathogenic metabolism of
Aβ in AD (Figure 4). Exploration for possible mechanisms
underlying Aβ accumulation in AD is crucial to resolve these
issues. There are growing and compelling data now avail-
able to implicate Aβ degradation in AD pathogenesis. Aβ
is a substrate of a wide range of proteases, which are likely
contribute to the accumulation of Aβ in AD. Both enzymatic
loss through genetic mutations and nongenetic factors, such
as direct oxidative damage or enhanced production of in-
hibitors, may contribute to aberrant Aβ catabolism. Current
results from in vitro and animal models support NEP, IDE,
ECE, and ACE as probable enzymes for Aβ degradation, but
data from humans remain largely missing. Due to clear limi-
tations of animal models, validation in human subjects with
AD will be critical to establish the physiologic signiﬁcance
of these proteases. Measurement of brain Aβ levels, amyloid
pathology and clinical cognitive performance with enzyme
activity, location and expression will help to clarify which of
these many enzymes that are capable of cleaving Aβ are actu-
ally key players in human disease.Deng-Shun Wang et al 7
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Figure 4: Possible brain Aβ clearance mechanisms. Aβ peptides may be removed by enzymatic degradation within brain parenchyma
[38, 173] or they can be transported through the blood-brain-barrier into the blood or CSF by receptor for advanced glycation endproducts
(RAGE), ApoE, β-2-macroglobulin, and the low-density lipoprotein receptor (LRP) [3, 174–176] .T h es t e a d y - s t a t el ev e lo fb ra i nA β depends
upon a balance between production and catabolism. Increased production (like in familial AD) and/or decreased clearance (for most spo-
radic AD) will result in elevated brain Aβ levels and potentially trigger or accelerate the pathogenesis of AD. RAGE: receptor for advanced
glycation end products; LRP: low-density lipoprotein receptor-related protein.
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